乳腺断层合成联合对比增强乳腺摄影在具有乳腺癌个人史女性中的乳腺癌检出:前瞻性TOCEM试验中期分析
前瞻性TOCEM试验中期分析纳入具有乳腺癌个人史的女性,每年同时行数字乳腺断层合成(DBT)和对比增强乳腺摄影(CEM),由两名观察者交叉判读。加用CEM后第1年癌症检出率由15.7/1000升至22.8/1000(增量检出率7.1/1000),第2+3年由3.8/1000升至7.6/1000(增量检出率3.8/1000),但召回率相应增加约5.0%-6.6%。仅CEM检出的18例乳腺癌中13例(72%)为浸润性癌,中位肿瘤大小0.6 cm。
要点
- 具有乳腺癌个人史的女性在DBT基础上加用CEM可提高早期乳腺癌检出率。
- 加用CEM后第1年增量癌症检出率为7.1/1000次筛查,第2+3年为3.8/1000次筛查。
- 加用CEM伴随召回率增加约5.0%-6.6%。
核心结论
- 在具有乳腺癌个人史的女性中,DBT基础上加用CEM可提高每年的早期乳腺癌检出率,同时伴随约5.0%-6.6%的召回率增加。
研究设计与样本
- 前瞻性TOCEM试验中期分析,计划连续3年每年同时行DBT和CEM筛查,由两名放射科医生交叉判读(观察者1先DBT后CEM,观察者2先CEM后DBT)。
关键影像表现/征象
- 仅CEM检出的18个乳腺中,13个(72%)为浸润性癌,中位肿瘤大小0.6 cm。
- 仅CEM检出且有分期的9个乳腺中,8个(88%)为N0。
- 1883次参考标准充分的筛查中,发生3例间期癌(1例位于瘢痕处,2例位于腋窝)。
诊断标准与关键数值
- 观察者1第1年癌症检出率:DBT单独15.7/1000次筛查(20/1273)vs DBT+CEM 22.8/1000次筛查(29/1273),增量癌症检出率7.1/1000次筛查(95%CI:3.2,13.4),P < .001。
- 观察者1第2+3年癌症检出率:DBT单独3.8/1000次筛查(4/1046)vs DBT+CEM 7.6/1000次筛查(8/1046),增量癌症检出率3.8/1000次筛查(95%CI:1.0,7.6),P = .001。
- 观察者1第1年召回率:DBT单独8.1%(103/1273)vs DBT+CEM 14.7%(187/1273),差值6.6%(95%CI:5.3,8.1),P < .001。
- 观察者1第2+3年召回率:DBT单独3.8%(40/1046)vs DBT+CEM 8.8%(92/1046),差值5.0%(95%CI:3.7,6.3),P < .001。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Digital breast tomosynthesis (DBT) is often inadequate for screening women with a personal history of breast cancer (PHBC). The ongoing prospective Tomosynthesis or Contrast-Enhanced Mammography, or TOCEM, trial includes three annual screenings with both DBT and contrast-enhanced mammography (CEM). Purpose To perform interim assessment of cancer yield, stage, and recall rate when CEM is added to DBT in women with PHBC. Materials and Methods From October 2019 to December 2022, two radiologists interpreted both examinations: Observer 1 reviewed DBT first and then CEM, and observer 2 reviewed CEM first and then DBT. Effects of adding CEM to DBT on incremental cancer detection rate (ICDR), cancer type and node status, recall rate, and other performance characteristics of the primary radiologist decisions were assessed. Results Among the participants (mean age at entry, 63.6 years ± 9.6 [SD]), 1273, 819, and 227 women with PHBC completed year 1, 2, and 3 screening, respectively. For observer 1, year 1 cancer yield was 20 of 1273 (15.7 per 1000 screenings) for DBT and 29 of 1273 (22.8 per 1000 screenings; ICDR, 7.1 per 1000 screenings [95% CI: 3.2, 13.4]) for DBT plus CEM (P < .001). Year 2 plus 3 cancer yield was four of 1046 (3.8 per 1000 screenings) for DBT and eight of 1046 (7.6 per 1000 screenings; ICDR, 3.8 per 1000 screenings [95% CI: 1.0, 7.6]) for DBT plus CEM (P = .001). Year 1 recall rate for observer 1 was 103 of 1273 (8.1%) for (incidence) DBT alone and 187 of 1273 (14.7%) for DBT plus CEM (difference = 84 of 1273, 6.6% [95% CI: 5.3, 8.1]; P < .001). Year 2 plus 3 recall rate was 40 of 1046 (3.8%) for DBT and 92 of 1046 (8.8%) for DBT plus CEM (difference = 52 of 1046, 5.0% [95% CI: 3.7, 6.3]; P < .001). In 18 breasts with cancer detected only at CEM after integration of both observers, 13 (72%) cancers were invasive (median tumor size, 0.6 cm) and eight of nine (88%) with staging were N0. Among 1883 screenings with adequate reference standard, there were three interval cancers (one at the scar, two in axillae). Conclusion CEM added to DBT increased early breast cancer detection each year in women with PHBC, with an accompanying approximately 5.0%-6.6% recall rate increase. Clinical trial registration no. NCT04085510 © RSNA, 2024 Supplemental material is available for this article.
引用
- Berg WA, Berg JM, Bandos AI, et al. Addition of Contrast-enhanced Mammography to Tomosynthesis for Breast Cancer Detection in Women with a Personal History of Breast Cancer: Prospective TOCEM Trial Interim Analysis. Radiology. 2024. PMID: 38687218. doi:10.1148/radiol.231991
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。